Abstract: Disclosed are systems and methods of detecting an impulse of energy given off by an injection device and determining a dosage of medicine based on the impulse. In one example, a module detects the vibrations given off by dialing a click-wheel on an autoinjector and determining the selected dosage of medicine based on the dialed dosage.

Abstract: Disclosed are systems and methods of detecting an impulse of energy given off by an injection device and determining a dosage of medicine based on the impulse. In one example, a module detects the vibrations given off by dialing a click-wheel on an autoinjector and determining the selected dosage of medicine based on the dialed dosage.

Abstract: The invention relates to a method for estimating a negative pressure at a wound site during a negative pressure wound therapy. The method comprises the steps of determining a negative pressure value by means of a pressure sensor, determining a pump speed associated with the electrical pump, multiplying the pump speed by a constant to obtain a modification value, and combining said modification value with the negative pressure value determined by means of the pressure sensor to obtain a modified negative pressure value. Said modified negative pressure value corresponds to the estimated negative pressure present at the wound site. The invention further relates to a negative pressure wound therapy system adapted to execute said method of estimating a negative pressure at a wound site.

Abstract: Disclosed are systems and methods of detecting an impulse of energy given off by an injection device and determining a dosage of medicine based on the impulse. In one example, a module detects the vibrations given off by dialing a click-wheel on an autoinjector and determining the selected dosage of medicine based on the dialed dosage.

Abstract: Disclosed are systems and methods of detecting an impulse of energy given off by an injection device and determining a dosage of medicine based on the impulse. In one example, a module detects the vibrations given off by dialing a click-wheel on an autoinjector and determining the selected dosage of medicine based on the dialed dosage.

Abstract: A portable negative pressure wound therapy device adapted to be carried by a user, comprising an electrically actuated suction pump for draining wound fluids from a patient, at least one microelectronic controller, at least one electronic memory and a housing for containing the electrical and/or electronic components. The device further comprises at least one microelectronic impact sensor, wherein the impact sensor is adapted to detect an impact acting on the device.

Abstract: The invention relates to a method for estimating a negative pressure at a wound site during a negative pressure wound therapy. The method comprises the steps of determining a negative pressure value by means of a pressure sensor, determining a pump speed associated with the electrical pump, multiplying the pump speed by a constant to obtain a modification value, and combining said modification value with the negative pressure value determined by means of the pressure sensor to obtain a modified negative pressure value. Said modified negative pressure value corresponds to the estimated negative pressure present at the wound site. The invention further relates to a negative pressure wound therapy system adapted to execute said method of estimating a negative pressure at a wound site.

Abstract: Disclosed are systems and methods of detecting an impulse of energy given off by an injection device and determining a dosage of medicine based on the impulse. In one example, a module detects the vibrations given off by dialing a click-wheel on an autoinjector and determining the selected dosage of medicine based on the dialed dosage.

Abstract: The invention provides methods for modulation interactions between MDL-1 and its binding partner, Gal9. Also provided are methods to screen for modulators of MDL-1/Gal9 interaction.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: The invention provides methods for modulation interactions between MDL-1 and its binding partner, Gal9. Also provided are methods to screen for modulators of MDL-1/Gal9 interaction.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: The invention provides methods of introducing diversity into antibody molecules comprising introducing or substituting at least one amino acid sequence in the CDR of the target antibody together with at least one amino acid in the FW region spanning the 3 amino acid adjoining the CRD on each side. The resulting diverse antibodies with variant CDRs and FW region sequences comprising diverse amino acid sequences are also described. These polypeptides regions, herein referred to as 3+CDR3+, that form the gist of the invention contribution described herein provide a flexible and simple source of sequence diversity that can be used as a source for expressing and identifying diverse antibodies or antigen binding polypeptides. Libraries comprising a plurality of these polypeptides are also provided. In addition, methods of and compositions for generating and using these polypeptides and libraries are provided.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: The present invention provides a structure-based methodology for efficiently generating and screening a library of recombinant antibodies for optimized antibodies with desirable functions, such as higher binding affinity or low immunogenicity. In one embodiment, a method is provided for constructing a library of antibody sequences based on a three dimensional structure of a lead antibody. The method comprises: providing a lead structural template comprising the amino acid sequence of the variable region of the heavy chain (VH) or light chain (VL) of a lead antibody, comparing the lead template sequence with a plurality of tester protein sequences; selecting a hit library from the tester protein sequences; determining if a member of the hit library is structurally compatible with the lead structural template using a scoring function; selecting members for the hit library that score equal to or better than the lead sequence and screening members for improved function(s).

Abstract: Methods and systems are provided for constructing recombinant antibody libraries based on three-dimensional structures of antibodies from various species including human. In one aspect, a library of antibodies with diverse sequences is efficiently constructed in silico to represent the structural repertoire of the vertebrate antibodies. Such a functionally representative library provides a structurally diverse and yet functionally more relevant source of antibody candidates which can then be screened for high affinity binding to a wide variety of target molecules, including but not limited to biomacromolecules such as protein, peptide, and nucleic acids, and small molecules.

Abstract: The present invention provides novel anti-CD26 antibodies and other, related polypeptides, as well as novel polynucleotides encoding the antibodies and polypeptides. The invention also provides methods of making the antibodies and polypeptides. Compositions and cells comprising the antibodies or polypeptides are further provided. Methods of using the antibodies and/or polypeptides, such as to inhibit cell proliferation and in the treatment of conditions associated with CD26, are also provided.

Abstract: The present invention provides a methodology for efficiently generating and screening protein libraries for optimized proteins with desirable biological functions, such as improved binding affinity towards biologically and/or therapeutically important target molecules. The process is carried out computationally in a high throughput manner by mining the ever-expanding databases of protein sequences of all organisms, especially human.

Abstract: Methods are provided for designing and selecting antibodies against human antigens with high affinity and specificity in silico and in vitro. In some particular embodiments, methods are provided for designing and selecting humanized or fully human antibodies against vascular endothelial growth factor (VEGF) with high affinity and specificity. In another aspect of the invention, monoclonal antibodies against VEGF are provided. In particular, humanized or human anti-VEGF monoclonal antibodies are provided with ability to bind to human VEGF with high affinity, inhibit VEGF-induced proliferation of endothelial cells in vitro and inhibit VEGF-induced angiogenesis in vivo. These antibodies and their derivative can be used in a wide variety of applications such as diagnosis, prevention, and treatment of diseases such as cancer, AMD, diabetic retinopathy, and other diseases derived from pathological angiogenesis.